Bio-Rad Laboratories (NYSE:BIO) was upgraded by equities researchers at TheStreet from a “hold” rating to a “buy” rating in a research report issued on Thursday, StockRatingsNetwork.com reports. Bio-Rad Laboratories, Inc. (NYSE:BIO) shares after opening at $126.49 moved to $128.76 on last trade day and at the end of the day closed at $128.27. Company price to sales ratio in past twelve months was calculated as 1.73 and price to cash ratio as 6.05. Bio-Rad Laboratories, Inc. (NYSE:BIO) showed a negative weekly performance of -0.76%.
BTIG Research began coverage on shares of Abiomed (NASDAQ:ABMD). They issued a neutral rating on the stock. ABIOMED, Inc. (NASDAQ:ABMD) shares advanced 0.55% in last trading session and ended the day on $25.74. ABMD return on equity ratio is recorded as 5.10% and its return on assets is 4.20%. ABIOMED, Inc. (NASDAQ:ABMD) yearly performance is 46.50%.
Investment analysts at Canaccord Genuity initiated coverage on shares of Alphatec Holdings (NASDAQ:ATEC) in a note issued to investors on Tuesday, TheFlyOnTheWall.com reports. The firm set a “buy” rating on the stock. Alphatec Holdings Inc (NASDAQ:ATEC) shares moved up 6.25% in last trading session and was closed at $1.70 while trading in range of $1.65 – $1.79 – Alphatec Holdings Inc (NASDAQ:ATEC) year to date (YTD) performance is -15.42%.
Sunshine Heart (NASDAQ:SSH) shares tumbled 10.16% to $7.25 after the company reported weaker-than-expected Q4 earnings. Sunshine Heart Inc (NASDAQ:SSH) weekly performance is 5.11%. On last trading day company shares ended up $6.58. Sunshine Heart Inc (NASDAQ:SSH) distance from 50-day simple moving average (SMA50) is -27.02%. Analysts mean target price for the company is $13.50.